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Purpose: The purpose of this study was to evaluate the functional relevance of longi-
tudinal changes in hyperautofluorescent areas and flecks in Stargardt disease (STGD1)
using short-wavelength autofluorescence (SW-AF) imaging.
Methods: In this prospective, longitudinal study, 31 patients with STGD1 (56 eyes)
underwent microperimetry (MP) and SW-AF imaging twice in 3 to 5 years. A total of
760 MP test points were included in the statistical analysis based on stable fixation
and accurate alignment of SW-AF and MP. Autofluorescence intensity was qualita-
tively assessed in all MP test points. Small circumscriptive hyperautofluorescent lesions
were defined as flecks. Longitudinal imaging characteristics observed on SW-AF were
classified into the following categories: appearing, disappearing, and stable flecks,
stable hyperautofluorescent, and stable background autofluorescence. The relationship
between SW-AF intensity changes and MP changes was analyzed using a linear mixed
model corrected for baseline sensitivity.
Results: Retinal sensitivity declined most in locations without change in SW-AF inten-
sity. Functional decline per year was significantly larger in flecks that disappeared
(−0.72± 1.30 dB) compared to flecks that appeared (−0.34± 0.65 dB), if baseline sensi-
tivity was high (≥10 dB; P < 0.01). The correlation between the change observed on
SW-AF and the sensitivity change significantly depended on the sensitivity at baseline
(P = 0.000).
Conclusions: Qualitative longitudinal assessment of SW-AF poorly reflected the retinal
sensitivity loss observed over the course of 3 to 5 years.
Translational Relevance: When aiming to assess treatment effect on lesion level, a
multimodal end point including MP focused on hyperautofluorescent lesions appears
essential but needs further studies on optimizing MP grids, eye-tracking systems, and
alignment software.
Introduction
Autosomal recessive Stargardt disease (STGD1) is
the most prevalent inherited macular dystrophy and
there currently are no viable treatment options.1 In
STGD1, mutations in the gene encoding the ATP-
binding cassette transporter A4 (ABCA4) impair
the removal of retinal from the photoreceptor disks
and retinal pigment epithelium (RPE) endolysosomes,
which results in lipofuscin accumulation in the RPE.2,3
Over time, this leads to destruction of both the RPE
and the overlying photoreceptors with severe visual
impairment as a result.4–6 In recent years, different
treatment options for STGD1 have been in develop-
ment, some of which are currently being tested in
clinical trials. Strategies vary from stem-cell therapy
and genetic therapy (e.g. gene augmentation therapy
with lentiviruses; and RNA therapy with antisense
oligonucleotides) to pharmacological agents aimed
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at preventing lipofuscin accumulation.7,8 However,
because STGD1 has a relative slow rate of progres-
sion and sensitive end points, to test the benefit of these
newly found therapies have not been established yet.
Yellow-white flecks and chorioretinal atrophy
centered around the posterior pole are the hallmark
features of STGD1. These lesions can be readily
distinguished on ophthalmoscopy, although these
are better delineated using short-wavelength fundus
autofluorescence (SW-AF) imaging. SW-AF imaging
typically shows intensely fluorescent pisciform flecks in
the macula, often extending to the midperiphery, and
macular hypo-autofluorescent areas corresponding to
areas of RPE atrophy.9–11 SW-AF imaging allows for
objective and fast measurement of the extent of RPE
atrophy, which has been correlated to loss of function
measured using microperimetry (MP) and visual
acuity.12–14 Therefore, RPE atrophy measured using
SW-AF imaging has become a major biomarker of
disease progression and an end point in three out of six
phase II/III clinical trials for STGD1 (Supplementary
Table S1). However, RPE atrophy growth generally
is slow and variable, both challenging the ability
of this biomarker to detect short-term treatment
effect.15–18 Additionally, the potential of this imaging
biomarker as a primary end point is limited by trial
design (e.g. trials in early disease stages, prior to RPE
atrophy).
The potential of hyperautofluorescence and partic-
ularly flecks, an early hallmark of STGD1, as a
biomarker for progression is less evident. The small,
pisciform lesions that appear hyperautofluorescent on
SW-AF imaging correspond to hyper-reflective bands
on spectral-domain optical coherence tomography.19
In longitudinal natural history studies, flecks centrifu-
gally expand outward from the central macula and
their intensity on SW-AF imaging increases and subse-
quently declines over time leaving residual atrophy.20–26
Especially these regions of visible disease activity in
early stages might be interesting loci to include in a
progression biomarker. Previous studies also demon-
strated a characteristic general background increase
in autofluorescence signal in patients with STGD1.27
In clinical trials, especially those aimed at lipofuscin
reduction, these autofluorescence patterns might serve
as a biomarker to prove treatment effect.Knowledge on
the correlation between autofluorescence patterns and
retinal function is required to assess the potential of
SW-AF imaging change as treatment outcome, because
primary efficacy end points in late-phase clinical trials
should reflect clinical benefit to provide substantial
evidence of effectiveness.28
MP is a fundus guided visual field test, which enables
functional follow-up of selected retinal areas or lesions
in time. Microperimetric mean sensitivity showed a
decline within 1 year in patients with STGD1 and
may therefore serve as a useful end point for clinical
trials.29,30 Indeed, STGD1 flecks that appear hyperaut-
ofluorescent on SW-AF imaging have been associated
with a significantly lower retinal sensitivity, measured
by MP, compared to the nearest non-flecked areas.
Conversely the sensitivity of these hyperautofluores-
cent flecks is significantly higher compared to hypo-
autofluorescent flecks.31,32 On the other hand, nasal
and temporal segments of STGD1 eyes with elevated
levels of autofluorescence had preserved retinal sensi-
tivity.33 However, longitudinal data on the correla-
tion between autofluorescence patterns of lipofuscin-
laden regions on SW-AF imaging during follow-up
and retinal function still are limited. The purpose of
this study is to correlate SW-AF imaging changes,
especially in hyperautofluorescent flecks and areas with
retinal sensitivity change measured using MP.
Methods
Subjects
This prospective, longitudinal study was conducted
at the Department of Ophthalmology at the Radboud
UniversityMedical Center. This study was approved by
the local ethics committee and adhered to the tenets of
the Declaration of Helsinki. All patients gave written
informed consent prior to enrollment.
Patients with a clinical diagnosis of STGD1,
supported by the identification of one or two disease-
causing ABCA4 alleles were included between 2013
and 2015. The clinical diagnosis was made based
on the presence of macular, irregular shaped flecks,
that appear yellow-white on ophthalmoscopy, hyper-
autofluorescent on SW-AF imaging in combination
with progressive macular atrophy. Participants under-
went MP and SW-AF imaging during 2 visits; visit
1 between 2013 and 2015 and visit 2 in 2018. Other
variables collected were best-corrected visual acuity
(Snellen), age at onset, and disease duration. Age at
onset was defined as the onset of first visual complaints
attributable to STGD1 disease reported by the patient.
The disease duration was defined as the time between
the age at onset and the study visit.
Image Acquisition and Selection of Eyes
Macular sensitivity was assessed by perform-
ing MP with the Nidek MP1 (Nidek Technologies,
Padova, Italy). This system ensures the correct projec-
tion of stimuli on the corresponding infrared (IR)
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Figure 1. Examples of quality assessment of the data alignment between both visits, after coregistration of MP with SW-AF images. The
data of the first visit (images A1, B1, C1, and D1) was compared to data of the second visit (images A2, B2, C2, and D2).
ophthalmoscopic image of the retina by using an
integrated eye tracking system. Each MP measure-
ment was performed under mesopic light conditions
and prior to SW-AF imaging. The nontested eye was
occluded. Patients were asked to focus on a 2 degrees
diameter red fixation target, leading to the preferred
retinal loci (PRL) as the center of the MP grid. Full-
threshold fundus perimetry was performed by using
a 4-2-1 staircase and 40-point strategy. Goldmann II
standard size stimuli were presented for 200 millisec-
onds. Eight points were tested at 1 degree from the
PRL, and 16 points were tested at 3 degrees and 5
degrees from the PRL, respectively. The Nidek MP1
simultaneously assesses fixation stability based on the
Fujii criteria.34 Fixation was classified as “stable”when
75% of fixations were located within a 2 degrees diame-
ter circle; as “relatively unstable” if ≥ 75% of fixations
were located within a 4 degrees diameter circle and as
“unstable” if < 75% of fixations were located within a
4 degrees diameter circle. AnMP training programwas
performed prior to the baseline test to reduce learning
effects. During follow-up, the manufacturer’s follow-up
protocol was used.
SW-AF imageswere taken using a confocal scanning
laser ophthalmoscope with an optically pumped
solid-state laser with 488-nm excitation (Spectralis;
Heidelberg Engineering, Heidelberg, Germany) after
adequate pupil dilatation. En face SW-AF images of
30 degrees and 55 degrees were acquired (Automatic
Real Time [ART] ≥15).
Using the Microperimeter MP1 software (Navis
Software, version 1.7; Nidek Technologies, Inc.)
SW-AF images were imported and coregistered with
the MP data. Two retinal vessel bifurcations in each
image were selected as coregistration landmarks. To
correct for distortion, the quality of the alignment
was judged by two independent graders (P.P.A.D. and
E.H.R.). Alignment of MP1 with SW-AF imaging
between baseline and follow-up was compared and
qualitatively classified as “good” (MP test points on
the exact same location), “moderate” (MP test points
partially overlapped), or “bad” (MP test points did not
overlap or macular sensitivity >0 was measured in the
optic disk; Fig. 1).
Eyes were excluded from further analyses if the
image quality was poor (n= 3), alignment of the multi-
modal imaging was considered bad (n = 18), or the
fixation was unstable at either visit (n= 33). As a result,
only 19 eyes of 12 patients fitted both the fixation and
alignment criteria and were included in the analysis.
Supplementary Figure S1 and Supplementary Table S2
gives a detailed overview of the selected eyes.
Image Grading
The SW-AF imaging intensity relative to the image
background was graded at each point of the MP grid.
Hence, points were qualified as background autoflu-
orescence, hyperautofluorescent (more intense than
background), or hypo-autofluorescent (less intense
than background; Fig. 2). Hyperautofluorescent
lesions were further divided into hyperautofluorescent
areas (characteristic pattern of diffuse background
increase of SW-AF imaging)35 or an STGD1 fleck
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Figure 2. At the MP test points SW-AF imaging intensity was graded as background autofluorescence, hyperautofluorescent area, hyper-
autofluorescent circumscriptive lesion (fleck), or hypo-autofluorescent.
Table. Categories of Longitudinal SW-AF Characteristics
Category SW-AF Visit 1 SW-AF Visit 2
Stable background autofluorescence (n = 303) Background autofluorescence Background autofluorescence
Stable hyperautofluorescent (n = 17) Hyperautofluorescent area Hyperautofluorescent area
Stable fleck (n = 17) Hyperautofluorescent circumscript lesion Hyperautofluorescent circumscript lesion
Appearing fleck (n = 26) Background autofluorescence Hyperautofluorescent circumscript lesion
Disappearing fleck, change to hypo-autofluorescent (n = 26) Hyperautofluorescent circumscript lesion Hypo-autofluorescent
Disappearing fleck, change to hyperautofluorescent (n = 12) Hyperautofluorescent circumscript lesion Hyperautofluorescent area
SW-AF, short-wavelength fundus autofluorescence imaging.
(small hyperautofluorescent circumscriptive lesion).19
Grading was performed by two independent graders
(P.P.A.D. and E.H.R.) and was discussed until agree-
ment was reached.
Based on the cross-sectional SW-AF imaging
grading, five categories of longitudinal SW-AF
imaging characteristics were defined, as specified
in the Table.
Statistical Analysis
The correlation between image characteristics and
microperimetry was assessed using a linear mixed
model, in which the functional change in MP over
time was the dependent variable and the SW-AF
imaging category was the main independent variable.
We accounted for variations between patients and
between the eyes of each patient by using two levels.
All measurements were nested within the eyes (eyes
as level) and the eyes were nested within the patients
(patients as level). To correct for possible confound-
ing, the following continuous covariables were consid-
ered: baseline macular sensitivity, follow-up time, and
disease duration. From the possible confounders, only
baseline sensitivity appeared to be associated with
functional change. In order to provide a better insight
in the relationship between the functional change
and the two predictors, we also modeled baseline
microperimetry as a dichotomous instead of a contin-
uous outcome variable. For this purpose, macular
sensitivity 0 to 9 was labeled as “low MP,” and
macular sensitivity 10 to 20 was labeled as “high MP.”
AP< 0.05was considered to be statistically significant.
Results
Thirty-one patients with STGD1 (10 men and
21 women) were enrolled in this study. Four patients
had early-onset STGD1 (age at onset ≤10 years),
22 patients had intermediate-onset STGD1 (age at
onset 11–44 years), and 5 patients had late-onset
STGD1 (age at onset ≥45years). Median follow-up
time was 4 years (range = 3–5 years). At follow-up, the
mean age was 45 ± 15 years (range = 20–69 years),
and the mean visual acuity in the right eye and left
eye was 20/143 (decimal = 0.14 ± 0.22, range = 0.16–
0.80) and 20/200 (decimal= 0.10± 0.14, range= 0.02–
1.0), respectively. None of the patients had concomi-
tant ocular disease and all included eyes were phakic
with clear media. The participants’ characteristics are
described in Supplementary Table S3.
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Figure 3. The linear mixed model shows that the retinal sensitivity change over time not only depends on the longitudinal SW-AF
imaging intensity over time but also on the baseline sensitivity as is depicted in (A). Although no SW-AF imaging change over time was
observed in lesions of category “stable hyperautofluorescent,”the retinal sensitivity in these loci decreased. (B) Displays themodel-estimated
marginalmeans and 95% confidence interval per defined category. Significant differences in functional declinewere found between several
categories in regions with high initial sensitivity. *P < 0.05.
Because of fixation and alignment criteria only
19 of 56 eyes were included in the analysis. A total of
760 MP test points (40 locations for each eye) were
categorized based on the corresponding local autoflu-
orescence intensity. Two hundred sixty-four locations
were graded as hyperautofluorescent, of which 98
MP test points were located on a fleck. Mean retinal
sensitivity in these flecks was 11.75 ± 6.88 dB. Between
baseline and follow-up, 38 of these flecks disappeared
and 26 flecks appeared. Mean baseline sensitivity
of appearing flecks (16.69 ± 5.24 dB) was higher
compared to disappearing flecks (10.32 ± 7.75 dB) and
the estimated functional decline per year was larger
(−0.34 ± 0.65 dB in appearing flecks and −0.72 ±
1.30 dB in disappearing flecks). Retinal sensitivity
did not change over time when background SW-AF
imaging intensity remained constant (i.e. the category
“stable background autofluorescence” [−0.16 ±
0.51 dB per year]).
A linear mixed model was conducted to model the
sensitivity change as a function of the longitudinal
imaging characteristics, the baseline sensitivity, and the
interaction termof the latter two. The other covariables
“follow-up time” and “disease duration” had no signif-
icant correlation with the sensitivity change over time
and were therefore not used in the model.
The effect of the longitudinal SW-AF imaging
category on the sensitivity change over time signifi-
cantly depended on the baseline sensitivity (interac-
tion baseline sensitivity * SW-AF imaging change,
P = 0.000): as expected, the retinal sensitivity showed
a larger decline if the sensitivity at baseline was
relatively preserved. The relation between the retinal
sensitivity and the defined categories of longitudi-
nal imaging characteristics is visualized in Figure 3.
Regions of hyperautofluorescence at baseline showed
the largest sensitivity decline. Interestingly, the retinal
sensitivity declined most in regions that did not
show a change in SW-AF imaging intensity over
time (i.e. regions that remained hyperautofluorescent).
The model with retinal sensitivity as a dichotomous
variable (see Fig. 3B) clearly shows significant differ-
ences in functional decline between the several defined
categories in regions with high initial sensitivity.
Discussion
This study addressed the relationship between quali-
tatively assessed longitudinal imaging characteristics
on SW-AF imaging and retinal sensitivity over time.
Knowledge on the correlation between autofluores-
cence patterns and retinal function is required to
assess these biomarkers as treatment outcome, because
primary efficacy end points in late-phase clinical trials
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should reflect clinical benefit to provide substantial
evidence of effectiveness. To allow for adequate assess-
ment of SW-AF imaging changes and the retinal sensi-
tivity in time on lesion level, we included 19 out of
56 eyes (34%), of 12 out of 31 patients, because the
other eyes had a bad fixation or there was an improper
alignment of the examination modalities of follow-up
to baseline. For the longitudinal analysis of subfield
sensitivity variables in ProgStar Report No. 13, the
use of follow-up function and good or fair pattern
placement limited the count of eyes from 359 to 106
(30%).29 Limitations that cause this loss of data mostly
relate to inclusion of patients with advanced disease
stage. Despite the use of the integrated eye-tracking
system, unstable fixation impaired the reliability of MP
measurements. Additionally, the coregistration of MP
and SW-AF imaging may have been imperfect because
manual coregistration using two landmarks does not
correct for distortion.We have corrected this by strictly
assessing the quality of the alignment. However, inade-
quate alignment could have affected the accuracy of the
correlation between SW-AF imaging and MP to some
degree. In order to obtain comparable MP measure-
ments over time, we used the same hardware and
software between 2013 and 2018. However, techniques
used in microperimetry have been improved. Next
to this, recent advances in imaging techniques have
provided newways to assess the characteristics of flecks
(e.g. fluorescence lifetime imaging ophthalmoscopy
and quantitative autofluorescence).36,37 With these
techniques, longitudinal imaging characteristics can be
assessed in a quantitative way instead of via qualita-
tive analysis as we did in this study. In order to longi-
tudinally study the retinal sensitivity in specific lesions
in more detail, new data should be obtained using the
most recent advancements in technology. Despite the
limitations we encountered, a total of 760 MP test
points were considered as well aligned and of sufficient
quality to accurately assess the correlation between the
longitudinal SW-AF imaging characteristics and the
retinal sensitivity.
Mean retinal sensitivity in flecks was comparable
to the 12.89 ± 3.86 dB reported by others.31 This
study also supports the evidence that background
autofluorescence, which is generally hyperautofluores-
cent in STGD1 eyes as compared with normal eyes,
is not associated with loss of function.27,33 To our
best knowledge, there are no previous reports on the
correlation between autofluorescence patterns during
follow-up and retinal function. Our data demonstrated
that the retinal sensitivity declined in loci where a
new fleck appeared as well as in loci where a fleck
disappeared, during a follow-up time of 3 to 5 years.
Moreover, loci of stable flecks and disappearing flecks
showed a larger functional decrease than loci of flecks
that arose. These data fit the hypothesis that, during the
pathological process of flecks appearing, fading, and
leaving residual atrophy, the retinal sensitivity shows
a progressive decline over time, and progression rate
might even increase during this process.4–6
The structural basis of flecks is still under debate.
Because lipofuscin accumulation in RPE cells is one of
the hallmarks in STGD pathogenesis, flecks have long
been assumed to be lipofuscin-laded RPE cells.2,3,38
Recent examination of flecks across multiple imaging
modalities indicated that flecks might reflect groups
of photoreceptor cells degenerating after the loss
of RPE.37 Yet, recent histology correlations suggest
that flecks corresponded to subretinal macrophages
packed with pigment granules (lipofuscin, melanin,
and melanolipofuscin).39 Our data show that retinal
sensitivity in flecks is not lost and even can remain
stable during several years of follow-up. Therefore, our
data contradict hypotheses of flecks representing dead
photoreceptor cells. Further work is required to estab-
lish the histopathological substrate of flecks.
In the hyperautofluorescent regions and flecks that
did not show SW-AF imaging change over time, the
retinal sensitivity declined most according to the statis-
tical model. Because of the inability to distinguish
qualitative differences, SW-AF imaging does not seem
a good measure of preservation of function. The same
was concluded from the observation that areas of
reduced AF were not compatible with the area of
dense scotoma in patients with STGD1.40 In our post
hoc analysis, the functional decline in a stable fleck
was significantly larger compared to stable background
autofluorescence regions and appearing flecks, when
sensitivity at baseline was defined as high (>10 dB).
Because these histopathological changes over timewere
not discernable with SW-AF imaging only, a multi-
modal end point approach is needed when it comes to
selecting outcome measures for clinical trials.
This study focused on hyperautofluorescent lesions
as the autofluorescent pattern of lipofuscin might
serve as a biomarker to prove treatment effect of
clinical trials aiming at lipofuscin reduction. When
the tested loci were hyperautofluorescent at baseline
(i.e. the defined categories stable hyperautofluores-
cent, stable fleck, and disappearing fleck), they showed
a larger decline in sensitivity as compared to loci
that were hypo-autofluorescent or the same level as
the background autofluorescence at baseline. This
makes baseline hyperautofluorescence an interesting
biomarker as it might predict a functional decline over
time in those areas. Baseline retinal sensitivity might
serve as inclusion criterium for clinical trials, despite the
described limitations of MP, because our data showed
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that regions with higher sensitivity at baseline allowed
for a better differentiation of sensitivity changes over
time in relation to SW-AF imaging changes over time.
In conclusion, SW-AF imaging does not adequately
reflect the retina’s functional change over time and,
therefore, is not suitable as the sole primary end point in
trials. For the evaluation of hyperautofluorescence and
STGD1 flecks in clinical trials, a multimodal end point
including MP focused on hyperautofluorescent lesions
could have great potential. However, further studies
that make use of improved eye-tracking systems as well
as advanced software to allow accurate coregistration
of retinal examination modalities are required to assess
the added value of MP in a multimodal end point.
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